Please be aware that this website is not intended for consumers, as the information provided herein does not refer to finished commercial products that are generally available to the public.
The claims made refer to ingredients only and may not comply with Regulation (EC) No. 1924/2006, the Swiss Federal Act on Foodstuffs and Utility Articles (and related Ordinance), the Swiss Ordinance of the Internal Affairs Department on Information concerning Foodstuffs and Cosmetics, or other relevant regulations in your country. Any claims or statements about the products relating to their health benefits have not been evaluated by the Food and Drug Administration (FDA) and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Any of the ingredients are intended to diagnose, treat, cure, or prevent any disease or health condition.
This website is accessible from various countries around the world. Therefore, it may include statements or information that are not applicable to your country or region.
Improving lives with high-quality, science-based cannabinoid active pharmaceutical ingredients
Since its founding in 1982, Linnea has focused on developing top-tier plant-based Active Pharmaceutical Ingredients at its GMP-certified facility in Switzerland. Known for its dedication to excellence, Linnea ensures every ingredient adheres to rigorous standards, with a particular emphasis on the compliance of herbal starting materials with GACP standards.
This marked the beginning of our commitment to applying the same science-based, uncompromising approach to the pharmaceutical manufacturing of cannabinoids from natural Cannabis Sativa L. for customers worldwide.
This positions the company as one of the very few industry leaders devoted to the highest levels of quality, ensuring sustained growth and cutting-edge advancements through 2025 and beyond.
We supply GMP pharmaceutical preparations in bulk for companies and pharmacies under GID “Guarantee of Identity”. Ready-to-market products are in compliance with the Swiss Pharmacopoeia.
Linnea implements a short supply chain model to preserve the integrity of the phytocomplex. Linnea’s handling of cannabinoid ingredients is fully compliant with international import/export regulations for controlled substances.
Linnea is pleased to invite you to meet our team at these upcoming international events:
JANUARY
30 January
SED (Conference on cannabis-based medicines)
Madrid, Spain
Ilustre Colegio Oficial de Médicos de Madrid
> Visit conference web page
FEBRUARY
9–12 February
WHX (World Health Expo)
Dubai, UAE
Dubai Exhibition Centre
> Meet us at booth #S11.D94
19 February
CANNABIS EUROPA
Paris, France
Hôtel de l’Industrie
> Meet us at our booth
MARCH
2–3 March
euroPLX
Lisbon, Portugal
Hotel Cascais Miragem
Book an appointment > [email protected]
9–10 March
Med-Cannabis
Krakow, Poland
Hotel Metropolo by Golden Tulip
Book an appointment > [email protected]
Schedule your live or virtual appointment now with the Linnea team:
